CSIMarket
 


Aimmune Therapeutics Inc   (AIMT)
Other Ticker:  
 

Cumulative Aimmune Therapeutics Inc 's Total Debt to Equity for Trailing Twelve Months Period

AIMT's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

AIMT Total Debt to Equity for Trailing Twelve Months Period

(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Equity Growth -12.25 % -8.29 % -65.2 % -38.22 % -28.79 %
Y / Y Total Debt Growth 241.23 % 244.13 % - - -
Total Debt to Equity for Trailing Twelve Months Period 0.51 0.36 0.22 0.13 0.08
Total Ranking # 1783 # 1470 # 1109 # 757 # 574
Seq. Equity Growth -23.48 % 125.95 % -31.87 % -25.51 % -20.03 %
Seq. Total Debt Growth 2.5 % 212.59 % 3.13 % 3.26 % 3.38 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2020
On the trailing twelve months basis Due to net new borrowings of 2.5%, Total Debt to Equity for Trailing Twelve Months Period improved to 0.51, a new company high.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 181 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Aimmune Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
AIMT Charts and Quotes
Total Debt to Equity AIMT in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 182
Sector # 371
S&P 500 # 2095


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.51 0.22 0.03
(Jun 30 2020)   (Mar 31 2019)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Ptc Therapeutics inc   1.25 
Verastem inc   1.24 
First Wave Biopharma Inc   1.13 
Mylan N v   1.11 
Cannapharmarx Inc   1.10 
Redhill Biopharma Ltd   1.10 
Bristol myers Squibb Company  1.08 
Innoviva Inc   1.07 
Insmed Inc  1.06 
Merck and Co Inc   1.03 
Karyopharm Therapeutics Inc   1.00 
Integrated Biopharma Inc  0.98 
Novabay Pharmaceuticals Inc   0.94 
Collegium Pharmaceutical Inc   0.92 
Obseva Sa  0.91 
Reata Pharmaceuticals Inc   0.88 
Durect Corp  0.87 
Biodelivery Sciences International Inc   0.86 
Phathom Pharmaceuticals Inc   0.86 
Pacira Biosciences inc   0.84 
Pfizer Inc  0.84 
Aveo Pharmaceuticals Inc   0.82 
Sunwin Stevia International Inc.  0.81 
Lipocine Inc   0.79 
Fortress Biotech Inc   0.78 
Travere Therapeutics Inc   0.77 
Kala Bio inc   0.76 
Siga Technologies Inc  0.76 
Progenics Pharmaceuticals Inc  0.76 
Emergent Biosolutions Inc   0.75 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com